Yuan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuan Zhang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
BoChong Wei
Department of Thoracic Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, People’s Republic of China
1 shared publication- George Fu Gao
Strategic Pandemic Preparedness Action and Research Center (SPARC), Guangzhou National Laboratory
1 shared publication - Guang Zhu
Department of Pathology & Cancer Research Center, Yanbian University Medical College, Yanji, 133002, China
1 shared publication - Hai Li
Department of Gastroenterology, Renji Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases Shanghai China
1 shared publication - Hao Chi
Department of Quantitative Health Sciences, John A. Burns School of Medicine University of Hawaii at Manoa Honolulu Hawaii USA
1 shared publication Hao-Xiang Yuan
Department of Thoracic Surgery and Oncology, The first affiliated hospital of Guangzhou medical university, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 August 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (8) , 6045-6065
Lipid metabolism-related genes regulate the immune microenvironment during ex vivo lung perfusion for lung transplants
Background: Ex vivo lung perfusion (EVLP) serves as a vital platform for donor lung assessment and repair in transplantation. Although lipid metabolism plays a crucial role in pulmonary homeostasis and undergoes alterations during EVLP, the precise regulatory mechanisms linking metabolic changes to immune modulation remain poorly understood. This study aimed to identify key lipid metabolism-related genes governing immune microenvironment remodeling during EVLP and to validate their diagnostic and therapeutic potential. Methods: We analyzed transcriptomic profiles from human donor lungs before and after EVLP using datasets GSE127057 (discovery cohort) and GSE127055 (validation cohort). A comprehensive analytical framework was implemented, incorporating weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) networks, and three machine learning algorithms including least absolute shrinkage and selection operator (LASSO) regression, Random Forest (RF), and eXtreme Gradient Boosting (XGBoost) to identify key lipid metabolism-related genes. Immune cell infiltration patterns were characterized using established computational methods, with subsequent validation in an EVLP model of C57BL/6J wild-type mice. Results: Analysis of GSE127057 revealed 656 differentially expressed genes (DEGs) post-EVLP. Through integrative bioinformatics approaches, three lipid metabolism-related hub genes (UGCG, SAMD8, MED26) were identified as consistently upregulated. These genes demonstrated significant positive correlations with resting natural killer (NK) cell populations and negative associations with activated NK cells. The diagnostic potential of these biomarkers was confirmed through receiver operating characteristic (ROC) analysis, achieving an area under curve (AUC) of 0.986 in the discovery cohort (GSE127057) and 0.922 in the independent validation cohort (GSE127055). Experimental validation in murine EVLP models recapitulated the significant upregulation of all three hub genes. Conclusions: This study establishes UGCG, SAMD8, and MED26 as central regulators of lipid metabolism during EVLP, with their expression patterns correlating with NK cell functional states. These findings provide mechanistic insights into metabolic-immune interactions during donor lung preservation and identify potential biomarkers for clinical monitoring and therapeutic targeting.
- 1 August 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (8) , 6045-6065
Open AccessLipid metabolism-related genes regulate the immune microenvironment during ex vivo lung perfusion for lung transplants
Background: Ex vivo lung perfusion (EVLP) serves as a vital platform for donor lung assessment and repair in transplantation. Although lipid metabolism plays a crucial role in pulmonary homeostasis and undergoes alterations during EVLP, the precise regulatory mechanisms linking metabolic changes to immune modulation remain poorly understood. This study aimed to identify key lipid metabolism-related genes governing immune microenvironment remodeling during EVLP and to validate their diagnostic and therapeutic potential. Methods: We analyzed transcriptomic profiles from human donor lungs before and after EVLP using datasets GSE127057 (discovery cohort) and GSE127055 (validation cohort). A comprehensive analytical framework was implemented, incorporating weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) networks, and three machine learning algorithms including least absolute shrinkage and selection operator (LASSO) regression, Random Forest (RF), and eXtreme Gradient Boosting (XGBoost) to identify key lipid metabolism-related genes. Immune cell infiltration patterns were characterized using established computational methods, with subsequent validation in an EVLP model of C57BL/6J wild-type mice. Results: Analysis of GSE127057 revealed 656 differentially expressed genes (DEGs) post-EVLP. Through integrative bioinformatics approaches, three lipid metabolism-related hub genes (UGCG, SAMD8, MED26) were identified as consistently upregulated. These genes demonstrated significant positive correlations with resting natural killer (NK) cell populations and negative associations with activated NK cells. The diagnostic potential of these biomarkers was confirmed through receiver operating characteristic (ROC) analysis, achieving an area under curve (AUC) of 0.986 in the discovery cohort (GSE127057) and 0.922 in the independent validation cohort (GSE127055). Experimental validation in murine EVLP models recapitulated the significant upregulation of all three hub genes. Conclusions: This study establishes UGCG, SAMD8, and MED26 as central regulators of lipid metabolism during EVLP, with their expression patterns correlating with NK cell functional states. These findings provide mechanistic insights into metabolic-immune interactions during donor lung preservation and identify potential biomarkers for clinical monitoring and therapeutic targeting.
- Open Access
- 20 January 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (1) , 101374
Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors
- 20 January 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (1) , 101374
Open AccessDiscovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors
- Open Access
- 21 February 2022
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 7 (1) , 1-4
Nasal delivery of thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection
- 21 February 2022
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 7 (1) , 1-4
Open AccessNasal delivery of thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection
- Open Access
- 1 November 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 11157-11167
The Long Noncoding RNA Linc01833 Enhances Lung Adenocarcinoma Progression via MiR-519e-3p/S100A4 Axis
Introduction: Lung cancer (LC) is among the most prevalent malignancies worldwide, with extremely high morbidity and mortality rates. Mounting evidence has suggested that the abnormally expressed long noncoding RNA (lncRNA) in lung cancer tissues may play vital roles in tumor progression. In the present research, we aimed to examine the functions and underlying mechanism of linc01833 in lung adenocarcinoma (LUAD). Methods: qRT-PCR was employed to determine transfection efficiency. CCK-8, transwell invasion assay, Western blotting analysis and qRT-PCR were used to detect proliferation as well as migration of different LUAD cell lines, and were also applied to determine the changes during epithelial–mesenchymal transformation (EMT). Afterwards, bioinformatics and dual-luciferase reporter assay were utilized to explore and to identify the potential corresponding targets of linc01833 and miR-519e-3p. Results: Linc01833 OE can significantly improve proliferation as well as invasion ability of LC cells and promote the EMT process. Dual-luciferase reporter assay demonstrated that linc01833 could directly bind to miR-519e-3p, thereby inhibiting its expression. Further experiments showed that S100A4 was a direct target of miR-519e-3p. Rescue assay demonstrated that linc01833 acted on the miR-519e-3p/S100A4 axis. Conclusion: We verified the mechanism of linc01833 in promoting infiltration and metastasis in LUAD. To be specific, linc01833 can function as a competitive endogenous RNA (ceRNA) to adsorb miR-519e-3p through a sponge and regulate S100A4 in lung cancer, thereby being involved in LUAD progression. Collectively, our research provides new insights towards the in-depth understanding of LC progression mechanisms.
- 1 November 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 11157-11167
Open AccessThe Long Noncoding RNA Linc01833 Enhances Lung Adenocarcinoma Progression via MiR-519e-3p/S100A4 Axis
Introduction: Lung cancer (LC) is among the most prevalent malignancies worldwide, with extremely high morbidity and mortality rates. Mounting evidence has suggested that the abnormally expressed long noncoding RNA (lncRNA) in lung cancer tissues may play vital roles in tumor progression. In the present research, we aimed to examine the functions and underlying mechanism of linc01833 in lung adenocarcinoma (LUAD). Methods: qRT-PCR was employed to determine transfection efficiency. CCK-8, transwell invasion assay, Western blotting analysis and qRT-PCR were used to detect proliferation as well as migration of different LUAD cell lines, and were also applied to determine the changes during epithelial–mesenchymal transformation (EMT). Afterwards, bioinformatics and dual-luciferase reporter assay were utilized to explore and to identify the potential corresponding targets of linc01833 and miR-519e-3p. Results: Linc01833 OE can significantly improve proliferation as well as invasion ability of LC cells and promote the EMT process. Dual-luciferase reporter assay demonstrated that linc01833 could directly bind to miR-519e-3p, thereby inhibiting its expression. Further experiments showed that S100A4 was a direct target of miR-519e-3p. Rescue assay demonstrated that linc01833 acted on the miR-519e-3p/S100A4 axis. Conclusion: We verified the mechanism of linc01833 in promoting infiltration and metastasis in LUAD. To be specific, linc01833 can function as a competitive endogenous RNA (ceRNA) to adsorb miR-519e-3p through a sponge and regulate S100A4 in lung cancer, thereby being involved in LUAD progression. Collectively, our research provides new insights towards the in-depth understanding of LC progression mechanisms.
- Open Access
- 1 February 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 1741-1752
The prognostic value of Tiam1 correlates with its roles in epithelial–mesenchymal transition progression and angiogenesis in lung adenocarcinoma
Background: Tiam1 has been identified as an oncogene and acts as an activator of GTPase Rac. Tiam1 was reported to be a promoter of cancer progression in various cancer types, while in lung adenocarcinoma, its mechanism of action is poorly understood. Materials and Methods: Immunohistochemistry staining and Western blot assay were used to determine Tiam1 expression in lung adenocarcinoma tissues, and its association with prognosis was determined by statistical analysis. We depleted Tiam1 in both A549 and H1975 cancer cell lines. Carboxyfluorescein diacetate succinimidyl ester staining and colony formation assays were used to evaluate its impact on cell proliferation ability after depletion. Transwell migration assay and wound healing assays were performed to determine its impact on migration ability of both cell lines. Western blot assay and immunofluorescence staining were used to analyze the association between Tiam1 and epithelial–mesenchymal transition (EMT) progression. Tube formation assay and vasculogenic mimicry assay were used to show the impact of Tiam1 depletion on cancer angiogenesis. Results: In this study, we demonstrated that Tiam1 overexpression in lung adenocarcinoma was significantly associated with advanced tumor grade and poor prognosis. In vitro assays indicated that Tiam1 depletion significantly inhibited cell proliferation, colony formation, and migration capacities in A549 and H1975 cells. Further investigations revealed that Tiam1 plays an important role in EMT program enhancement, angiogenesis, and accelerated tumor progression. Notably, Tiam1 depletion in cancer cells strongly inhibited human umbilical vein endothelial cell angiogenesis and vasculogenic mimicry capacities of both cancer cell lines. Conclusion: Tiam1 overexpression is associated with lung adenocarcinoma progression and may indicate poor prognosis. Tiam1 accelerated tumor progression due to EMT and angiogenesis enhancement. Our data may provide a novel therapeutic target for lung adenocarcinoma.
- 1 February 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 1741-1752
Open AccessThe prognostic value of Tiam1 correlates with its roles in epithelial–mesenchymal transition progression and angiogenesis in lung adenocarcinoma
Background: Tiam1 has been identified as an oncogene and acts as an activator of GTPase Rac. Tiam1 was reported to be a promoter of cancer progression in various cancer types, while in lung adenocarcinoma, its mechanism of action is poorly understood. Materials and Methods: Immunohistochemistry staining and Western blot assay were used to determine Tiam1 expression in lung adenocarcinoma tissues, and its association with prognosis was determined by statistical analysis. We depleted Tiam1 in both A549 and H1975 cancer cell lines. Carboxyfluorescein diacetate succinimidyl ester staining and colony formation assays were used to evaluate its impact on cell proliferation ability after depletion. Transwell migration assay and wound healing assays were performed to determine its impact on migration ability of both cell lines. Western blot assay and immunofluorescence staining were used to analyze the association between Tiam1 and epithelial–mesenchymal transition (EMT) progression. Tube formation assay and vasculogenic mimicry assay were used to show the impact of Tiam1 depletion on cancer angiogenesis. Results: In this study, we demonstrated that Tiam1 overexpression in lung adenocarcinoma was significantly associated with advanced tumor grade and poor prognosis. In vitro assays indicated that Tiam1 depletion significantly inhibited cell proliferation, colony formation, and migration capacities in A549 and H1975 cells. Further investigations revealed that Tiam1 plays an important role in EMT program enhancement, angiogenesis, and accelerated tumor progression. Notably, Tiam1 depletion in cancer cells strongly inhibited human umbilical vein endothelial cell angiogenesis and vasculogenic mimicry capacities of both cancer cell lines. Conclusion: Tiam1 overexpression is associated with lung adenocarcinoma progression and may indicate poor prognosis. Tiam1 accelerated tumor progression due to EMT and angiogenesis enhancement. Our data may provide a novel therapeutic target for lung adenocarcinoma.